Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option

Kidney Int Rep. 2022 Jan 30;7(5):1115-1118. doi: 10.1016/j.ekir.2022.01.1065. eCollection 2022 May.

Charlotte Gabilan¹, Pierre Pfirmann², David Ribes¹, Claire Rigothier², Dominique Chauveau^{1

3

4}, Audrey Casemayou^{1

3}, Antoine Huart¹, Joost Schanstra³, Magali Colombat^{4

5}, Stanislas Faguer^{1

3

4}, Julie Belliere^{1

3

4}

¹ Department of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, Toulouse, France.
² Department of Nephrology, University Hospital of Bordeaux, Bordeaux, France.
³ French National of Health and Medical Research, U1297 (Institute of Metabolic and Cardiovascular Diseases), Toulouse, France.
⁴ University Paul Sabatier-Toulouse 3, Toulouse, France.
⁵ Department of Pathology, University Hospital of Toulouse, University Cancer Institute of Toulouse, Toulouse, France.

No abstract available

Keywords: ANCA-associated vasculitis; avacopan; usCD163.